生物活性 | |||
---|---|---|---|
描述 | Zopolrestat is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM[1]. Zopolrestat reduced infarct size by up to 61%, both in vitro (2 nM to 1 μM; EC50 = 24 nM) and in vivo (50 mg/kg). Zopolrestat reduced myocardial sorbitol concentration (index of AR activity) by >50%[2]. In the EIU rat eye AqH, both the number of infiltrating cells and protein concentrations of the inflammatory markers, TNF-alpha, NO, and PGE(2) were significantly higher than in the control rats, and inhibition of AR by zopolrestat (25 mg/kg, i.p.) suppressed the LPS-induced increases. The LPS-induced increased expression of AR, TNF-alpha, iNOS, and COX-2 proteins in the ciliary body, corneal epithelium, and retinal wall was also significantly inhibited by zopolrestat[3]. In addition, AR inhibitors (Zopolrestat) negate diabetes-evoked hypertension via ameliorating impaired endothelial relaxation and NO production[4]. Zopolrestat also exerts a protective effect on the slowly developing diabetic cataract, as well as reducing albuminuria and proteinuria[5]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.92mL 2.38mL 1.19mL |
23.84mL 4.77mL 2.38mL |
参考文献 |
---|